BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 9707616)

  • 21. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy.
    Novitzky N; Rubinstein R; Hallett JM; du Toit CE; Thomas VL
    Transplantation; 2000 Apr; 69(7):1358-63. PubMed ID: 10798754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
    de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
    J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapse after allogeneic BMT for chronic myeloid leukemia (CML) may be sustained by a small number of leukemic 'stem cells': a hypothesis.
    Frassoni F; Podestà M; Piaggio G; Pitto A; Figari O; Soracco M; Lint M; Fugazza G; Sessarego M; Bacigalupo A
    Bone Marrow Transplant; 1999 Sep; 24(6):689-91. PubMed ID: 10490738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
    Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
    Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.
    Shimoni A; Gajewski JA; Donato M; Martin T; O'Brien S; Talpaz M; Cohen A; Korbling M; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2001; 7(10):568-75. PubMed ID: 11760089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia.
    Gilleece MH; Dazzi F
    Leuk Lymphoma; 2003 Jan; 44(1):23-8. PubMed ID: 12691139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
    Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):87-92. PubMed ID: 24252361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after bone marrow transplantation.
    Castro FA; Palma PV; Morais FR; Voltarelli JC
    Braz J Med Biol Res; 2004 Feb; 37(2):201-6. PubMed ID: 14762574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macrophage inflammatory protein-1 alpha receptors are present on cells enriched for CD34 expression from patients with chronic myeloid leukemia.
    Chasty RC; Lucas GS; Owen-Lynch PJ; Pierce A; Whetton AD
    Blood; 1995 Dec; 86(11):4270-7. PubMed ID: 7492787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Baurmann H; Nagel S; Binder T; Neubauer A; Siegert W; Huhn D
    Blood; 1998 Nov; 92(10):3582-90. PubMed ID: 9808551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.
    Levenga H; Woestenenk R; Schattenberg AV; Maas F; Jansen JH; Raymakers R; De Mulder PH; van de Wiel-van Kemenade E; Schaap N; de Witte T; Dolstra H
    Bone Marrow Transplant; 2007 Sep; 40(6):585-92. PubMed ID: 17637687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes.
    Slavin S; Ackerstein A; Morecki S; Gelfand Y; Cividalli G
    Bone Marrow Transplant; 2001 Oct; 28(8):795-8. PubMed ID: 11781634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells.
    Norde WJ; Overes IM; Maas F; Fredrix H; Vos JC; Kester MG; van der Voort R; Jedema I; Falkenburg JH; Schattenberg AV; de Witte TM; Dolstra H
    Blood; 2009 Mar; 113(10):2312-23. PubMed ID: 19074734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
    Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
    Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.
    Schürch C; Riether C; Amrein MA; Ochsenbein AF
    J Exp Med; 2013 Mar; 210(3):605-21. PubMed ID: 23401488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
    Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
    Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.